Sep 28, 2026 · 60 min
Medical evidence tests the gap between better numbers and better outcomes
#540 Hotcakes: Varenicline by mail for smoking cessation, anticoagulation for intermediate risk AF, CAC score plus PREVENT, blood testing for CRC, oral PCSK9 inhibitors, and more
Across prevention, screening, and treatment decisions, the episode shows why modest absolute benefits and uncertain evidence demand individualized clinical judgment.
- 1Mailed varenicline may expand smoking-cessation access, but trial exclusions and treatment limitations constrain how broadly results apply.
- 2For intermediate-risk atrial fibrillation, low event rates and bleeding risk make anticoagulation a shared decision rather than an automatic prescription.
- 3Calcium scoring, oral PCSK9 inhibition, and lipoprotein(a) lowering illustrate why improved prediction or biomarkers may not translate into patient benefit.
Don't miss
The review of pelacarsen’s substantial lipoprotein(a) reduction without cardiovascular benefit crystallizes the episode’s biomarker-versus-outcomes argument.
The brief
Matthew F. Watto, Paul Nelson-Williams, and Rahul Ganatra use the Hotcakes format to examine recent studies through absolute benefit, trial limitations, and clinical applicability.
Mailed varenicline offers a practical route to smoking cessation, but recruitment, dosing, biochemical verification, and psychiatric exclusions complicate its primary-care reach.
A randomized anticoagulation trial in intermediate-risk atrial fibrillation produced few events, leaving modest absolute benefit and bleeding risk to be balanced patient by patient.
The hosts question how much coronary calcium adds to PREVENT risk prediction, especially when reclassification can incorrectly intensify or withhold preventive treatment.
Blood-based colorectal screening may help patients who decline stool or visualization tests, while oral PCSK9 inhibition and pelacarsen expose the limits of biomarker logic.
The episode’s clearest lesson is methodological: mechanistic plausibility and better numbers matter less than evidence that patients actually live longer or healthier lives.